BCMA Antibody Binding to Block BAFF and APRIL in Myeloma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, such as immunomodulators and protease inhibitors, are not curative and there is a need for more effective BCMA-targeting therapies.
Innovation Solution
Development of an antibody or antigen-binding fragment that specifically binds to BCMA, blocking its ligands BAFF and APRIL, and can be used in a multispecific antigen-binding molecule, chimeric antigen receptor, immune effector cell, or pharmaceutical composition for targeted cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (immunomodulators and protease inhibitors) are used, then symptom relief is achieved, but the disease cannot be cured and patients will eventually relapse
Solution Approach 1:
The patent changes the target parameter from conventional treatment mechanisms to BCMA-specific targeting. By designing antibodies that specifically bind to BCMA with high affinity (Kd < 10^-7 M), the treatment achieves curative potential by directly attacking the tumor's survival mechanism rather than providing temporary symptom relief
Solution Approach 2:
The patent extracts the critical survival function of BCMA from the complex immune system. By isolating and targeting BCMA specifically, the therapy separates the tumor's essential survival mechanism from normal immune function, enabling curative treatment without compromising overall immune health
2Reliability
If BCMA-targeting therapies are developed, then curative potential is improved, but the complexity of antibody design and production increases
Solution Approach 1:
The patent segments the antibody development process into modular components: defining specific binding epitopes on BCMA, selecting appropriate antibody formats (full-length, fragments, single-chain), and optimizing each component independently. This segmentation reduces overall complexity while maintaining curative potential
Solution Approach 2:
The patent creates a universal BCMA-targeting platform that can be applied to multiple therapeutic formats (antibodies, CARs, bispecific molecules). The core BCMA-binding mechanism is designed to be adaptable across different therapeutic modalities, reducing development complexity through reuse of fundamental binding principles
3Reliability
If high affinity BCMA binding is achieved, then treatment efficacy is improved, but the difficulty of screening cross-binding antibodies increases due to homology between human and monkey BCMA
Solution Approach 1:
The patent applies local quality by focusing antibody development on specific epitopic regions of BCMA that exhibit human-specific characteristics. By targeting locally distinct regions rather than attempting to create universally binding antibodies, the screening process becomes more manageable while maintaining high affinity for human BCMA
Solution Approach 2:
The patent uses intermediary models (such as transgenic animals or cell lines expressing human BCMA) as mediators in the screening process. These intermediaries allow systematic evaluation of antibody binding specificity without direct comparison to monkey BCMA, simplifying the detection and measurement of cross-binding characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody provides high affinity for BCMA, effectively blocking its ligands and offering a promising treatment option for multiple myeloma, potentially improving therapeutic outcomes.
Implementation Method 1
The antibody can block the binding of BCMA's natural ligands (such as BAFF, APRIL) to BCMA
Data Source
AI summary
The present invention relates to an antibody against a B-cell maturation antigen (BCMA) and the use thereof. Specifically, disclosed herein are an antibody specifically binding to BCMA or an antigen-binding fragment thereof, and an encoding nucleic acid, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof in the preparation of a pharmaceutical composition for treating diseases, for example, for treating tumors. The present invention has important significance for the development of a therapeutic BCMA antibody drug and a detection reagent.